Safety1

Additional Analysis   >   Long-term analysis   >   Safety
  • Safety profiles of tafamidis meglumine 80 mg, tafamidis meglumine 20 mg, and placebo were similar in ATTR-ACT1
  • In the LTE, 164 patients treated with tafamidis meglumine 80 mg transitioned to tafamidis free acid 61 mg
  • Incidence and types of adverse events (AEs) were similar, or lower, in patients treated with tafamidis meglumine 80 mg who transitioned to free acid 61 mg compared to the pooled tafamidis meglumine (80 mg and 20 mg) or placebo arms in ATTR-ACT1
No new safety concerns emerged in patients treated with tafamidis meglumine 80 mg or tafamidis free acid 61 mg in the LTE10

AE: adverse event; ATTR-ACT: Transthyretin Amyloidosis Cardiomyopathy Clinical Trial; LTE: long-term extension; TEAE: treatment-emergent adverse event.

1 | 2